(R)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid

Catalog No. :
ACSERU387
CAS No. :
58617-29-1
Molecular Formula :
C10H17NO4
Molecular Weight :
215.25

IUPAC Name:(tert-butoxycarbonyl)-D-proline

(R)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$84.00Login to see priceIn stockIn stock
250mg98%$140.00Login to see priceIn stockIn stock
1g98%$322.00Login to see priceIn stockInquiry
5g98%$1272.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid
IUPAC Name(tert-butoxycarbonyl)-D-proline
MDL No.MFCD02682668
Molecular FormulaC10H17NO4
Molecular Weight215.25
SMILESO=C([C@@H]1N(C(OC(C)(C)C)=O)CCC1)O
InChI KeyZQEBQGAAWMOMAI-SSDOTTSWSA-N
SynonymN-Boc-3,4-dehydro-D-proline;Boc-3,4-dehydro-D-proline;1H-Pyrrole-1,2-dicarboxylic acid, 2,5-dihydro-, 1-(1,1-dimethylethyl) ester, (2R)-;(2R)-1-[(tert-butoxy)carbonyl]-2,5-dihydro-1H-pyrrole-2-carboxylic acid;(2R)-N-Boc-3,4-dehydro-L-proline;(2R)-N-Boc-3,4-dehydro-D-proline
CAS No.58617-29-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACSERU387 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOFUT254 route compound structure diagram
    ACOFUT254344-25-2 In Stock
  4. Then
  5. ACSERU387 route product structure diagram
    ACSERU38758617-29-1 In Stock
Inquiry

2. ACSERU387 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACOFUT254 route compound structure diagram
    ACOFUT254344-25-2 In Stock
  2. Then
  3. ACSERU387 route product structure diagram
    ACSERU38758617-29-1 In Stock
Inquiry

Comments (0)